Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening

BACKGROUND: The taxane cabazitaxel (CBZ) is a promising treatment for docetaxel-resistant castration-resistant prostate cancer (CRPC). However, the survival benefit with CBZ for patients with CRPC is limited. This study used screening tests for candidate drugs targeting CBZ-resistant-related gene ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Hongo, Hiroshi, Kosaka, Takeo, Suzuki, Yoko, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023558/
https://www.ncbi.nlm.nih.gov/pubmed/34593983
http://dx.doi.org/10.1038/s41391-021-00426-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023558/
https://www.ncbi.nlm.nih.gov/pubmed/34593983
http://dx.doi.org/10.1038/s41391-021-00426-0

Ejemplares similares